Agenus (NASDAQ:AGEN) Stock Price Crosses Above Two Hundred Day Moving Average of $12.94

Agenus Inc. (NASDAQ:AGEN)’s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $12.94 and traded as high as $15.66. Agenus shares last traded at $15.23, with a volume of 533,815 shares.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Agenus in a report on Friday, May 24th. B. Riley dropped their price target on shares of Agenus from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 18th. Finally, StockNews.com started coverage on shares of Agenus in a research note on Wednesday, April 17th. They set a “hold” rating on the stock.

Agenus Stock Up 4.6 %

The firm has a market capitalization of $319.83 million, a PE ratio of -1.19 and a beta of 1.35. The firm’s fifty day simple moving average is $12.47 and its 200-day simple moving average is $12.94.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share for the quarter, beating the consensus estimate of ($3.58) by $0.54. The company had revenue of $28.01 million for the quarter, compared to analysts’ expectations of $40.70 million. As a group, analysts predict that Agenus Inc. will post -9.7 earnings per share for the current year.

Institutional Trading of Agenus

Large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its stake in Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 123,058 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Agenus by 1,959.9% in the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 720,629 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after purchasing an additional 4,134,232 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Agenus by 81.3% during the 1st quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 84,477 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Agenus by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 13,604 shares in the last quarter. 61.46% of the stock is currently owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.